Filter By Industry
Filter By Tag


Amyndas Pharmaceuticals Press releases

1 - 1 of 1 Press Release

Aug 27, 2014
Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria.

Amyndas Pharmaceuticals RSS Feed